Quemliclustat

DRUG14 trials

Sponsors

Gilead Sciences Inc., Arcus Biosciences Inc., Arcus Biosciences, Inc., Gilead Sciences, Jonsson Comprehensive Cancer Center

Conditions

Advanced Non-Small Cell Lung CancerAdvanced Upper Gastrointestinal Tract MalignanciesAndrogen-Resistant Prostatic NeoplasmsBile Duct CancerBiliary Tract CarcinomaBorderline Resectable Pancreatic AdenocarcinomaCastration Resistant Prostatic NeoplasmsCholangiocarcinoma

Phase 1

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

CompletedNCT04381832

Arcus Biosciences, Inc.Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Prostatic Cancer, Castration-Resistant +1

Start: 2020-07-07End: 2024-08-30Updated: 2025-07-22

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

RecruitingNCT05688215

Jonsson Comprehensive Cancer CenterBorderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma

Start: 2023-03-07End: 2027-03-02Target: 56Updated: 2026-05-22

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer

CompletedCTIS2024-511158-36-00

Arcus Biosciences Inc.Metastatic colorectal cancer

Start: 2021-08-05End: 2025-06-10Target: 57Updated: 2025-07-08

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

CompletedNCT07364214

Arcus Biosciences, Inc.Healthy Participants

Start: 2026-02-03End: 2026-04-06Updated: 2026-05-01

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

Not yet recruitingNCT07667335

Fred Hutchinson Cancer CenterLocally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma +10

Start: 2026-12-01End: 2029-07-16Target: 27Updated: 2026-06-25

Phase 2

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Active, not recruitingNCT05329766

Arcus Biosciences, Inc.Gastrointestinal Tract Malignancies

Start: 2022-06-10End: 2027-06-01Updated: 2026-07-02

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Active, not recruitingNCT05676931

Gilead SciencesAdvanced Non-Small Cell Lung Cancer

Start: 2023-02-21End: 2027-12-01Target: 400Updated: 2026-06-01

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

RecruitingNCT05915442

Catherine SpinaOligometastatic Prostate Cancer

Start: 2023-07-01End: 2028-12-31Target: 23Updated: 2025-05-20

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

Active, not recruitingNCT06048133

Nataliya UbohaBile Duct Cancer, Biliary Tract Carcinoma, Cholangiocarcinoma

Start: 2024-03-08End: 2027-07-01Target: 33Updated: 2026-07-09

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

RecruitingNCT06048484

Gulam ManjiPancreatic Ductal Adenocarcinoma

Start: 2024-05-10End: 2027-04-01Target: 60Updated: 2026-02-27

A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer

Active, not recruitingCTIS2022-502916-35-01

Gilead Sciences Inc.Advanced Non-Small Cell Lung Cancer

Start: 2024-03-27Target: 171Updated: 2025-09-10

A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients with Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

Active, not recruitingCTIS2024-511917-40-00

Arcus Biosciences Inc.Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies, Upper Gastrointestinal Tract Cancer

Start: 2022-09-13Target: 60Updated: 2025-12-11

Phase 3

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruitingNCT06608927

Arcus Biosciences, Inc.Metastatic Pancreatic Ductal Adenocarcinoma

Start: 2024-12-13End: 2030-11-30Target: 610Updated: 2026-07-02

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruitingCTIS2024-513317-12-00

Arcus Biosciences Inc.Metastatic Pancreatic ductal adenocarcinoma (mPDAC), Pancreatic cancer, Pancreatic ductal adenocarcinoma (PDAC)

Start: 2025-02-05Target: 258Updated: 2025-12-12

Related Papers

Abstract A008: TIGIT, CD155 (PVR), and Trop-2 expression characterization across histology and PD-L1 subgroups in non−small cell lung cancer (NSCLC)

Molecular Cancer Therapeutics2025-10-22

Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.

2025-10-184 citations

QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.

Journal of Clinical Oncology2024-06-011 citations

A phase 2 single-arm study testing SBRT, adenosine signaling modulation, and immune checkpoint inhibition for men with hormone-sensitive oligometastatic prostate cancer (SBRT-AMICO).

Journal of Clinical Oncology2024-01-29

AIRPanc: A phase 2, open-label, multicenter, randomized study evaluating neoadjuvant therapy targeting the adenosine immunosuppressive pathway in combination with immune checkpoint blockade and radiation therapy in patients with advanced pancreatic ductal adenocarcinoma who are candidates for surgical resection.

Journal of Clinical Oncology2024-01-20

EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer.

Journal of Clinical Oncology2023-11-0327 citations

ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2021-05-2013 citations